Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 122,710
  • Shares Outstanding, K 55,027
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,505 K
  • 60-Month Beta 1.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.87
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings -0.09 on N/A
  • Next Earnings Date 11/05/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +4.21%
on 11/19/21
2.74 -18.61%
on 11/01/21
-0.38 (-14.56%)
since 10/26/21
3-Month
2.14 +4.21%
on 11/19/21
2.95 -24.41%
on 08/31/21
-0.62 (-21.75%)
since 08/26/21
52-Week
2.14 +4.21%
on 11/19/21
6.06 -63.20%
on 04/08/21
-1.28 (-36.47%)
since 11/26/20

Most Recent Stories

More News
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027

Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...

ONCY : 1.8100 (-3.72%)
ONC.TO : 2.23 (-2.62%)
CLVS : 3.20 (-4.19%)
MRK : 79.16 (-3.79%)
AZN : 56.58 (+0.43%)
ARAY : 5.12 (-3.21%)
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

Multi-center trial is being conducted in collaboration with Roche and AIO   Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal...

ONCY : 1.8100 (-3.72%)
ONC.TO : 2.23 (-2.62%)
Two Trillion-Dollar Industries Being Transformed By Tech

Big money is pouring into two disruptive segments in two of the world’s biggest industries - ...

BEP : 35.86 (-1.43%)
PLUG : 40.25 (-6.20%)
TRUE.CN : 1.300 (-7.14%)
DXD : 8.88 (+5.09%)
TRIL.TO : 23.33 (+0.47%)
PBH.TO : 125.19 (-1.56%)
ONC.TO : 2.23 (-2.62%)
CRH.TO : 4.99 (+0.40%)
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021,...

ONCY : 1.8100 (-3.72%)
ONC.TO : 2.23 (-2.62%)
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector

A massive disruption now appears imminent in one of the world’s largest – and most important ...

TRUE.CN : 1.300 (-7.14%)
TREIF : 1.0400 (-5.27%)
TRIL.TO : 23.33 (+0.47%)
ONC.TO : 2.23 (-2.62%)
HEXO.TO : 1.47 (-4.55%)
FTRP.CN : 5.550 (+1.46%)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –October 14, 2021 – USA News Group  –  Compared to the Dow Jones Industrial Average which has gained an impressive 10.6%...

ONCY : 1.8100 (-3.72%)
ONC.TO : 2.23 (-2.62%)
SESN : 1.0800 (-0.92%)
CRXT : 5.23 (+3.56%)
ORPH : 3.30 (-2.94%)
JNJ : 159.20 (-0.65%)
Biotech Winners Emerging Amid Sector’s Current Bearish Run

Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and ...

ONC.TO : 2.23 (-2.62%)
ORPH : 3.30 (-2.94%)
JNJ : 159.20 (-0.65%)
SESN : 1.0800 (-0.92%)
CRXT : 5.23 (+3.56%)
ONCY : 1.8100 (-3.72%)
Oncology Space Rapidly Improving Cancer Therapies in Wake of Operation Warp Speed

VANCOUVER – USA News Group – Oncology data leader COTA recently released a recent survey ...

ONC.TO : 2.23 (-2.62%)
RHHBY : 48.4100 (+0.17%)
BMY : 56.53 (-0.49%)
PFE : 54.00 (+6.11%)
MRK : 79.16 (-3.79%)
ONCY : 1.8100 (-3.72%)
Stocks in play: Oncolytics Biotech Inc.

Announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating ...

ONC.TO : 2.23 (-2.62%)
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments

Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this...

ONCY : 1.8100 (-3.72%)
ONC.TO : 2.23 (-2.62%)
JSPR : 8.23 (+5.65%)
NRBO : 1.7800 (+10.56%)
BLRX : 2.60 (-1.52%)
ALLO : 17.98 (-3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 2.48
2nd Resistance Point 2.42
1st Resistance Point 2.33
Last Price 2.23
1st Support Level 2.18
2nd Support Level 2.12
3rd Support Level 2.03

See More

52-Week High 6.06
Fibonacci 61.8% 4.56
Fibonacci 50% 4.10
Fibonacci 38.2% 3.64
Last Price 2.23
52-Week Low 2.14

See More

Business Summary

Oncolytics Biotech Inc is a development stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar